JP2023514407A - 増強された活性を有するbcma car-t細胞 - Google Patents

増強された活性を有するbcma car-t細胞 Download PDF

Info

Publication number
JP2023514407A
JP2023514407A JP2022550184A JP2022550184A JP2023514407A JP 2023514407 A JP2023514407 A JP 2023514407A JP 2022550184 A JP2022550184 A JP 2022550184A JP 2022550184 A JP2022550184 A JP 2022550184A JP 2023514407 A JP2023514407 A JP 2023514407A
Authority
JP
Japan
Prior art keywords
cells
amino acid
caccr
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514407A5 (cg-RX-API-DMAC7.html
Inventor
レジーナ ジュンフィ リン
サイラー パノフスキ
シーザー アドルフォ ゾマー
ブラーコム トーマス ジョン バン
バーブラ ジョンソン サス
アルン バラクマラン
Original Assignee
アロジーン セラピューティクス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アロジーン セラピューティクス,インコーポレイテッド filed Critical アロジーン セラピューティクス,インコーポレイテッド
Publication of JP2023514407A publication Critical patent/JP2023514407A/ja
Publication of JP2023514407A5 publication Critical patent/JP2023514407A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022550184A 2020-02-24 2021-02-24 増強された活性を有するbcma car-t細胞 Pending JP2023514407A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062980914P 2020-02-24 2020-02-24
US62/980,914 2020-02-24
US202063020713P 2020-05-06 2020-05-06
US63/020,713 2020-05-06
US202063053409P 2020-07-17 2020-07-17
US63/053,409 2020-07-17
US202063092681P 2020-10-16 2020-10-16
US63/092,681 2020-10-16
PCT/US2021/019362 WO2021173630A1 (en) 2020-02-24 2021-02-24 Bcma car-t cells with enhanced activities

Publications (2)

Publication Number Publication Date
JP2023514407A true JP2023514407A (ja) 2023-04-05
JP2023514407A5 JP2023514407A5 (cg-RX-API-DMAC7.html) 2024-03-04

Family

ID=75108802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550184A Pending JP2023514407A (ja) 2020-02-24 2021-02-24 増強された活性を有するbcma car-t細胞

Country Status (15)

Country Link
US (1) US12036243B2 (cg-RX-API-DMAC7.html)
EP (1) EP4110805A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023514407A (cg-RX-API-DMAC7.html)
KR (1) KR20220145846A (cg-RX-API-DMAC7.html)
CN (1) CN115175929A (cg-RX-API-DMAC7.html)
AU (1) AU2021227191A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016657A2 (cg-RX-API-DMAC7.html)
CA (1) CA3167065A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022011684A2 (cg-RX-API-DMAC7.html)
IL (1) IL295470A (cg-RX-API-DMAC7.html)
MX (1) MX2022010340A (cg-RX-API-DMAC7.html)
PE (1) PE20221757A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552033A1 (cg-RX-API-DMAC7.html)
TW (1) TWI894211B (cg-RX-API-DMAC7.html)
WO (1) WO2021173630A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230138428A1 (en) * 2020-02-25 2023-05-04 Quell Therapeutics Limited Chimeric receptors for use in engineered cells
KR20230171994A (ko) 2021-04-16 2023-12-21 셀진 코포레이션 선행 줄기 세포 이식을 받은 환자에서의 t 세포 요법
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
KR20240137075A (ko) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 세포 조성물의 제조 방법
EP4499680A1 (en) * 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN117126856A (zh) * 2022-05-20 2023-11-28 上海雅科生物科技有限公司 以bcma胞外结构域为标记的基因、多肽、重组表达载体、基因工程化细胞及其应用
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
CN119836438A (zh) * 2022-09-19 2025-04-15 艾洛基治疗公司 B-细胞成熟抗原(bcma)抗独特型抗体
US20260166082A1 (en) 2022-11-02 2026-06-18 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN121532650A (zh) 2023-06-20 2026-02-13 艾洛基治疗公司 工程化的细胞的检测方法
US20260108629A1 (en) * 2024-08-14 2026-04-23 Kite Pharma, Inc. Vectors for production of therapeutic constructs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069004A1 (en) * 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
JP2018512153A (ja) * 2015-04-13 2018-05-17 ファイザー・インク B細胞成熟抗原を標的にするキメラ抗原受容体
WO2019169290A1 (en) * 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
JP2019528078A (ja) * 2016-08-26 2019-10-10 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 細胞治療のための構造的に活性なサイトカイン受容体
WO2020180694A1 (en) * 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Constitutively active chimeric cytokine receptors
WO2020180664A1 (en) * 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010613A (en) 1995-12-08 2000-01-04 Cyto Pulse Sciences, Inc. Method of treating materials with pulsed electrical fields
WO1998002558A2 (en) 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
WO2007075899A2 (en) 2005-12-21 2007-07-05 Maxygen, Inc. Dual agonist compounds and uses thereof
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
AU2015330017A1 (en) 2014-10-07 2017-04-27 Cellectis Method for modulating car-induced immune cells activity
EP3234145B1 (en) 2014-12-15 2019-06-05 Bellicum Pharmaceuticals, Inc. Methods for controlled activation or elimination of therapeutic cells
EP3250602A1 (en) 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
CA2974998C (en) 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
WO2016168612A1 (en) 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
GB201518816D0 (en) 2015-10-23 2015-12-09 Autolus Ltd Receptor
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
WO2018161064A1 (en) 2017-03-03 2018-09-07 F1 Oncology, Inc. Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
WO2019055946A1 (en) 2017-09-18 2019-03-21 F1 Oncology, Inc. METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY THEREOF
US11654158B2 (en) 2016-11-17 2023-05-23 2Seventy Bio, Inc. TGFBeta signal convertor
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
GB201702617D0 (en) 2017-02-17 2017-04-05 Autolus Ltd Receptor
SG11201908929VA (en) * 2017-03-31 2019-10-30 Univ Leland Stanford Junior Synthekine compositions and methods of use
GB201719557D0 (en) 2017-11-24 2018-01-10 Autolus Ltd Polypeptide
US11738047B2 (en) 2017-12-12 2023-08-29 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
CN112533942A (zh) * 2018-06-01 2021-03-19 华盛顿大学 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制
CN112368298A (zh) 2018-06-22 2021-02-12 凯德药业股份有限公司 嵌合跨膜蛋白及其用途
GB201814203D0 (en) 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069004A1 (en) * 2009-12-04 2011-06-09 Quest Diagnostics Investments Incorporated Mpl mutations in jak2 v617f negative patients with myeloproliferative disease
JP2018512153A (ja) * 2015-04-13 2018-05-17 ファイザー・インク B細胞成熟抗原を標的にするキメラ抗原受容体
JP2019528078A (ja) * 2016-08-26 2019-10-10 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 細胞治療のための構造的に活性なサイトカイン受容体
WO2019169290A1 (en) * 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
WO2020180694A1 (en) * 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Constitutively active chimeric cytokine receptors
WO2020180664A1 (en) * 2019-03-01 2020-09-10 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain

Also Published As

Publication number Publication date
CO2022011684A2 (es) 2022-08-30
PH12022552033A1 (en) 2023-11-20
AU2021227191A1 (en) 2022-08-25
IL295470A (en) 2022-10-01
WO2021173630A1 (en) 2021-09-02
CN115175929A (zh) 2022-10-11
PE20221757A1 (es) 2022-11-11
KR20220145846A (ko) 2022-10-31
US20210260118A1 (en) 2021-08-26
TW202146439A (zh) 2021-12-16
EP4110805A1 (en) 2023-01-04
MX2022010340A (es) 2022-09-19
CA3167065A1 (en) 2021-09-02
TWI894211B (zh) 2025-08-21
BR112022016657A2 (pt) 2022-12-20
US12036243B2 (en) 2024-07-16

Similar Documents

Publication Publication Date Title
US12036243B2 (en) BCMA CAR-T cells with enhanced activities
CN113508128B (zh) 组成型活性嵌合细胞因子受体
JP7254870B2 (ja) キメラ抗体受容体(CARs)の構成およびその使用方法
US20240016846A1 (en) Chimeric cytokine receptors bearing a pd-1 ectodomain
US11905528B2 (en) Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
US20190135894A1 (en) COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF
KR20190101979A (ko) 합성 면역 수용체 및 이의 사용 방법
JP2022545167A (ja) Tgfベータ結合ドメインを含むキメラサイトカイン受容体
US20220348633A1 (en) COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
RU2824672C2 (ru) Конститутивно активные химерные цитокиновые рецепторы
HK40084006A (zh) 活性增强的bcma car-t细胞
HK40063003B (en) Constitutively active chimeric cytokine receptors
HK40063003A (en) Constitutively active chimeric cytokine receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250805